Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-rhPSMA-7.3
- Development stage
- Preclinical
- Lead developer
- Blue Earth Diagnostics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
64Cu-rhPSMA-7.3 is an investigational radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical developed by Blue Earth Diagnostics (a Bracco company) for positron emission tomography (PET) imaging of prostate cancer. It consists of the single-diastereoisomer radiohybrid PSMA ligand rhPSMA-7.3 labeled with the positron-emitting radioisotope copper-64 (64Cu). Due to the longer half-life of copper-64 (12.7 hours) compared to fluorine-18 (110 minutes), 64Cu-rhPSMA-7.3 offers potential logistical advantages, high-contrast imaging, and next-day imaging capabilities. It binds to PSMA (glutamate carboxypeptidase 2) expressed on prostate cancer cells, allowing for the visualization of PSMA-positive lesions.
- Other names
- 64Cu-flotufolastatcopper-64 rhPSMA-7.3copper64 rhPSMA-7.3copper 64 rhPSMA-7.3
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-rhPSMA-7.3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-rhPSMA-7.3.